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Accurate quantification of minimal residual disease (MRD) duringtreatment of chronic myeloid leukemia (CML) guides clinical deci-sions. The conventional MRD method, RQ-PCR for BCR-ABL1
mRNA, reflects a composite of the number of circulating leukemic cells
and the BCR-ABL1 transcripts per cell.  BCR-ABL1 genomic DNA only
reflects leukemic cell number. We used both methods in parallel to deter-
mine the relative contribution of  the leukemic cell number to molecular
response. BCR-ABL1 DNA PCR and RQ-PCR were monitored up to 24
months in 516 paired samples from 59 newly-diagnosed patients treated
with first-line imatinib in the TIDEL-II study. In the first three months of
treatment, BCR-ABL1 mRNA values declined more rapidly than DNA.
By six months, the two measures aligned closely. The expression of
BCR-ABL1mRNA was normalized to cell number to generate an expres-
sion ratio. The expression of e13a2 BCR-ABL1 was lower than that of
e14a2 transcripts at multiple time points during treatment. BCR-ABL1
DNA was quantifiable in 48% of samples with undetectable BCR-ABL1
mRNA, resulting in MRD being quantifiable for an additional 5-18
months (median 12 months). These parallel studies show for the first
time that the rapid decline in BCR-ABL1 mRNA over the first three
months of treatment is due to a reduction in both cell number and tran-
script level per cell, whereas beyond three months, falling levels of 
BCR-ABL1 mRNA are proportional to the depletion of leukemic cells.
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Real-time reverse transcriptase quantitative PCR (RQ-PCR) for BCR-ABL1
mRNA is widely used for the routine monitoring of chronic myeloid leukemia
(CML) patients receiving tyrosine kinase inhibitor (TKI) therapy. The achievement
of molecularly-defined therapeutic targets during TKI treatment is associated with
superior progression-free and overall survival.1 The BCR-ABL1 mRNA level is a
composite measurement that reflects both the proportion of leukemic cells in the
sample, and the expression of BCR-ABL1 relative to its control gene. Pre-analytical
factors, such as the rate of degradation of the target mRNA, and methodological
factors, such as the efficiency of reverse transcription or the choice of control gene,
may have a significant influence on the final result of RQ-PCR.2,3 Substantial effort
has been invested to minimize variation due to such factors through the develop-
ment of an International Scale (IS) for BCR-ABL1.4
An alternative approach to overcome the variability in
RQ-PCR is to measure BCR-ABL1 genomic DNA, since
the overwhelming majority of chronic phase CML
patients will have a single copy of BCR-ABL1 and two
copies of an autosomal control gene in each leukemic cell.
In the past, this approach was not practical due to the
complexity of sequencing individual genomic break-
points. Almost all CML patients express one or both of the
two common BCR-ABL1 mRNA transcripts (e13a2,
e14a2), whereas the genomic fusion sequences involve
introns that are spliced out from the mRNA, and are
essentially unique to each individual patient.5 Advances in
sequencing technology have made it relatively simple to
detect BCR-ABL1 genomic breakpoints, and several meth-
ods have been published.6,7 
It should be emphasized that DNA PCR and RQ-PCR
are not expected to yield identical results. This is perhaps
best exemplified by the comparison of RQ-PCR with
metaphase karyotyping in CML, which shows that a par-
tial cytogenetic response [≤35% Philadelphia-positive
(Ph+) cells] is roughly equivalent to BCR-ABL1IS ≤10%.8
Whereas both techniques are clinically useful, measures of
the size of the CML clone the end point of each assay is
qualitatively different. BCR-ABL1 DNA PCR is analogous
to fluorescence in situ hybridization, in that both methods
measure the simple proportion of cells in a sample that
carry the Philadelphia rearrangement. 
We used quantitative BCR-ABL1 DNA techniques, Q-
PCR and digital PCR (dPCR), to monitor a cohort of
patients in the Australasian Leukaemia and Lymphoma
Group (ALLG) CML9 study (TIDEL-II).9 These results
were compared with routine RQ-PCR monitoring. Since
the number of copies of BCR-ABL1DNA is directly related
to the number of leukemic cells in a sample, we used DNA
and mRNA-based methods in order to determine the rela-
tive contribution of cell number and expression changes to
molecular response in CML. Secondly, where there were
differences between RQ-PCR and DNA PCR, we explored
whether these differences might provide additional pre-
dictive information concerning treatment response. 
Methods 
Patients’ characteristics and samples
Fifty-nine newly diagnosed chronic phase CML patients from
the TIDEL-II clinical trial9 were included in our study. Details of
these patients and of the samples analyzed are presented in the
Online Supplementary Appendix and Online Supplementary Tables S1
and S2. The overall clinical characteristics and treatment responses
of the selected cohort were not significantly different from those
of the overall study population. The subset of patients included
here were selected in three categories: undetectable MRD
(UMRD) achieved within the first 2 years (n=26); treatment failure
(n=9); and 24 additional patients not falling into either of the first
two categories. Treatment failure was defined following the
European LeukemiaNet (ELN) criteria as loss of complete hemato-
logic response, loss of complete cytogenetic response, loss of
major molecular response (MMR; BCR-ABL1IS ≤0.1%), kinase
domain mutations, or progression to accelerated phase/blast cri-
sis).10 
Peripheral blood samples for molecular analysis were collected
prior to commencing TKI treatment (baseline); at one, two, and
three months; and every three months thereafter up to 24 months.
RQ-PCR was performed centrally in the diagnostic laboratory of
SA Pathology, Adelaide, Australia, using the BCR control gene.11
The results were reported as BCR-ABL1/BCR% applying an IS
conversion factor (Online Supplementary Appendix).4 Chromosome
banding analysis was routinely performed at diagnosis in the
respective local laboratories. Samples with fewer than 10
metaphases were excluded from this analysis. 
All samples were collected with informed consent in accor-
dance with the Institutional Ethics-approved protocols and with
reference to the Declaration of Helsinki.
Breakpoint detection 
The BCR-ABL1 genomic DNA breakpoint was determined, as
previously described, in blood samples collected at diagnosis using
long range PCR with a single forward primer in BCR and multiple
reverse primers in ABL1 to amplify the breakpoint (Online
Supplementary Appendix).12,13 
Quantification of BCR-ABL1 DNA 
Genomic DNA was extracted from peripheral blood leukocytes.
The amount of amplifiable DNA in each sample was measured
using the GUSB control gene. The earlier assays were performed
using real-time Q-PCR with standard curves for both BCR-ABL1
(patient’s diagnostic DNA assigned a value of 100%) and GUSB
(plasmid) diluted in non-human DNA. Later assays used digital
PCR (dPCR) for both BCR-ABL1 and GUSB with the aim of
improving precision. Results were reported as 
BCR-ABL1/GUSB% (corrected for the two copies of GUSB per
cell) normalized against the individual patient’s diagnostic sample.
Further details are provided in the Online Supplementary Appendix
and Online Supplementary Figures S1-S3. 
Statistical analysis 
Statistical analysis was performed using the GraphPad Prism 7
statistical software (GraphPad Prism Inc., La Jolla, CA, USA).
Agreement between assays was assessed using the method of
Bland and Altman.14 Correlation between non-parametric values
was assessed using Spearman rank coefficient. Differences
between BCR-ABL1 DNA and mRNA measurements were com-
pared using a Mann-Whitney test. The cumulative incidence of
MMR and MR4.5 was calculated using the Fine and Gray regres-
sion method in R. Any event leading to the permanent discontin-
uation of imatinib/nilotinib (including treatment failure, intoler-
ance, and death) was treated as a competing risk. P<0.05 was con-
sidered statistically significant.
Results
Comparison between DNA and mRNA before treatment 
Since DNA Q-PCR quantifies BCR-ABL1 relative to the
diagnostic DNA, we considered only the absolute dPCR
values at diagnosis (n=29) and compared these values with
the corresponding mRNA levels and the percentage of 
Ph+ bone marrow metaphase cells. The median value of 
BCR-ABL1 DNA prior to TKI treatment was 100% by
karyotyping (range, 85-100%) and 84% (range, 45-164%)
by dPCR. The corresponding median BCR-ABL1IS value
was 70%, with values ranging from 3.7% to 425% (Figure
1A). Two of the 3 patients (#1 and #3) with low BCR-
ABL1IS mRNA had stored peripheral blood cells available
for interphase fluorescence in situ hybridization, which
showed excellent agreement with the BCR-ABL1 DNA
values obtained by dPCR (Table 1). Two of these 3
patients experienced treatment failure (blast crisis/sec-
ondary resistance with a kinase domain mutation) and the
third patient had ELN warning features at baseline (high
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Sokal score and additional clonal chromosomal abnormal-
ities in Ph+ cells) and failed to reach MMR by 12 months
and MR4.5 by 24 months. All 3 of these patients expressed
e13a2 BCR-ABL1 transcripts (one expressed both e13a2
and e14a2) and all had unusually low white blood cell
counts at study entry (<20x109/L) (Online Supplementary
Table S3). The post-treatment molecular responses of
these 3 patients are shown in Figure 1B-D. 
Agreement of Q-PCR and dPCR for BCR-ABL1 DNA
Forty-six serial samples from 9 patients on TKI treat-
ment were quantified by both Q-PCR and dPCR for BCR-
ABL1 DNA. The results were highly correlated (r=0.94,
P<0.0001). Agreement between the two methods was fur-
ther assessed using a Bland-Altman plot (Online
Supplementary Figure S4). The mean bias was -0.11-log
with the 95% limits of agreement ranging from -1.02-log
to 0.80-log (±8.1 fold) indicating that there was no system-
atic difference between the results obtained by the two
DNA PCR methods after diagnosis. In subsequent analy-
ses of BCR-ABL1 DNA during treatment the two sets of
data were combined. 
Faster reduction in BCR-ABL1 mRNA than DNA early in
treatment 
In our cohort of 59 patients, the quantified BCR-ABL1
mRNA and DNA results (undetectable values excluded)
were highly correlated across the range of values during
TKI treatment (r=0.88; P<0.0001) (Figure 2A). However,
during the first three months of therapy BCR-ABL1 DNA
values were significantly higher than mRNA, whereas
from six months onwards there was good agreement
between methods (Figure 2B). The median reduction in
BCR-ABL1IS from baseline to three months was 2.05-log
versus 1.75-log for BCR-ABL1 DNA (Online Supplementary
Figure S5). This bias was independent of the BCR-ABL1
DNA quantification method (seen with both dPCR and Q-
PCR; see Online Supplementary Figure S6).
Early molecular response assessment by BCR-ABL1
mRNA and DNA 
A reduction in BCR-ABL1IS to ≤10% at three months
[early molecular response (EMR)] has emerged as an early
treatment milestone that is strongly associated with later
achievement of optimal response and progression-free
survival.15,16 The predictive effect of EMR was confirmed
in the overall TIDEL-II study population of 210 patients.9
In this smaller subgroup, no patient with BCR-ABL1IS lev-
els >10% at three months went on to achieve MMR or
MR4.5. We tested the predictive value of BCR-ABL1 levels
by both mRNA and DNA at the 3-month landmark using
I.S. Pagani et al.
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Figure 1. DNA and mRNA prior to treatment. (A) Proportion of leukemic cells and BCR-ABL1 expression before treatment assessed by conventional cytogenetic analy-
sis (green), DNA dPCR (red) and RQ-PCR (blue). Three patients with discrepant DNA and mRNA values are highlighted (red square). (B-D) Molecular response of
patients (pts) with BCR-ABL1IS <10% despite DNA values close to 100%. Absolute DNA dPCR values are represented at diagnosis. TKI: tyrosine kinase inhibitor; Ph+:
Philadelphia positive; Und: undetectable. 
Table 1. BCR-ABL1 values in patients with low mRNA values relative to
DNA values.
Patient ID mRNA, IS% DNA dPCR, % iFISH, %
#1 6.96 88.0 99.4
#2 5.10 81.2 N/A
#3 3.70 101.8 87.8
IS: International Scale; dPCR: digital PCR; iFISH: interphase fluorescence in situ
hybridization; N/A: not available.
A B
C D
the established BCR-ABL1 transcript IS cut-offs of 10%
and 1%. Both mRNA and DNA levels were predictive of
later MMR and MR4.5, and the BCR-ABL1 DNA level did
not improve the predictive value of conventional RQ-PCR
(Online Supplementary Figure S7). The optimal BCR-ABL1
DNA cut-off for prediction of later molecular response
could not be determined in this study due to the small
number of patients and the potential bias due to the selec-
tion of patients on the basis of response. 
Transcript type and molecular response 
It has previously been reported that the BCR-ABL1 tran-
script type may influence treatment outcomes (reviewed
by Marum and Branford17). Consequently, we compared
molecular responses in patients having only e13a2 tran-
scripts (n=32) or only e14a2 transcripts (n=17). There was
no significant difference between BCR-ABL1IS levels
according to transcript type at any individual time point
(Figure 3A). However, BCR-ABL1 DNA was significantly
higher in e13a2 patients at multiple time points during
treatment (Figure 3B). The median BCR-ABL1 expression
ratio (mRNA%:DNA%) was 0.5 for e13a2 versus 1.09 for
e14a2 (P=0.0005) (Figure 3C). This analysis was repeated
using BCR-ABL1 DNA values from dPCR and Q-PCR sep-
arately and a similar pattern was observed (Online
Supplementary Figure S8).
Sensitivity of RQ-PCR and DNA PCR 
The median limit of detection achieved by RQ-PCR was
MR4.6 (range, 3.2-5.1 log) in comparison with MR5.2
(range, 4.6-5.7 log) for DNA PCR. BCR-ABL1 DNA was
detected in 42 of 86 samples with undetectable mRNA
(49%) with a median value of 0.002% (range, 0.0002-
0.07%). Two samples were mRNA-positive, DNA-nega-
tive with BCR-ABL1IS values of 0.003 and 0.02% (Figure
2A). The remaining 44 samples had undetectable 
BCR-ABL1 by both methods. The higher degree of sensi-
tivity using BCR-ABL1 DNA led to MRD being quantifi-
able for an additional 5-18 months (median 12 months) of
follow up. Samples collected after 24 months were not
analyzed, so in some patients the duration of quantifiable
MRD may have been longer than this estimate.
Discussion
BCR-ABL1 molecular monitoring by RQ-PCR is relied
upon to ensure that TKI-treated patients are on track to
achieve an optimal response, to define the end points of
clinical trials, and to determine criteria for a safe trial of
cessation of TKI therapy after having sustained a deep
molecular response.18-20 Molecular responses defined by
RQ-PCR have been shown to be robust indicators of clin-
BCR-ABL1 DNA monitoring of CML
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Figure 2. Comparison between mRNA and
DNA quantification of BCR-ABL1. (A)
Positive values from DNA (red) and mRNA
(blue) were compared during treatment until
24 months. The quantifiable mRNA and DNA
values were highly correlated, but at very
low levels 42 samples were positive by DNA
PCR only (red square). (B) The mRNA and
DNA values (number, median and interquar-
tile range) are shown for individual time
points up to 24 months. Note that the appar-
ent increase in RQ-PCR after 18 months is
due to the exclusion of RQ-PCR samples in
which there was undetectable BCR-ABL1.
*P<0.05; ***P<0.0001; Und.: unde-
tectable. 
ical outcome, yet the biology of BCR-ABL1 molecular
response is relatively complex. Key to this complexity is
the composite nature of the response: a reduction in the
ratio of BCR-ABL1 mRNA to a control gene could be due
to a reduction in the proportion of CML cells in the sam-
ple, a reduction in the expression of BCR-ABL1, an
increase in the expression of the control gene, or even a
change in the relative stability of these mRNA transcripts.
Since the number of copies of genomic BCR-ABL1 is
directly proportional to the number of leukemic cells, we
reasoned that measuring both BCR-ABL1 DNA and
mRNA would lead to a better understanding of the main
determinants of variation in molecular response.
During the first three months of treatment, the 
I.S. Pagani et al.
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Figure 3. BCR-ABL1 transcript type and molecular response. (A)
Comparison of the BCR-ABL1IS values during the first two years of tyrosine
kinase inhibitor (TKI) treatment (e13a2 shown in green and e14a2 shown
in black). (B) Comparison of e13a2 and e14a2 BCR-ABL1 DNA values in
the same patients. Diagnostic values were assigned a value of 100%. Note
that at later time points the proportion of e14a2 patients with unde-
tectable BCR-ABL1 DNA was higher than for e13a2, which may result in an
underestimation of the difference between the two transcript types. (C)
Box and whiskers plot comparing BCR-ABL1 expression ratio (mRNA:DNA)





Months since starting TKI treatment
Months since starting TKI treatment
BCR-ABL1 DNA values were significantly higher than the
corresponding BCR-ABL1IS values. After three months, the
reduction in BCR-ABL1IS levels (2.05-log) was primarily
due to depletion of CML cells (1.75-log), with only a small
contribution from expression changes (0.3-log reduction;
2-fold decrease). A proportionally greater decline in
expression than in cell number is likely due to the early
depletion of higher expressing cells. From six months of
treatment onwards, there was generally excellent agree-
ment between the level of MRD measured by BCR-ABL1
DNA and by RQ-PCR, indicating that the decline in 
BCR-ABL1IS is closely paralleled by declining numbers of
BCR-ABL1-positive cells, as has been predicted using
mathematical models based on RQ-PCR data.21,22 
Several studies dating back at least two decades have
reported inferior treatment responses among CML
patients with e13a2 BCR-ABL1 transcripts.17,23 Differences
in molecularly-defined end points might simply reflect dif-
fering amplification efficiency in the BCR-ABL1 assay,
especially in those systems that use a common forward
primer in BCR e13, resulting in a 76 bp difference in ampli-
con length between the two transcripts.24 In BCR-ABL1
DNA PCR, every patient-specific assay will have differing
properties due to varying amplicon size and nucleotide
composition. These differences are determined by factors
related to the precise intronic location of the breakpoints,
and therefore independent of the transcript type (Online
Supplementary Figure S3). We took advantage of this to
compare the relative expression of e13a2 and e14a2 
BCR-ABL1 transcripts by normalizing the BCR-ABL1IS
value against BCR-ABL1 DNA. Patients expressing both
e13a2 and e14a2 transcripts were excluded from this
analysis; in those cases the genomic BCR breakpoint is
after exon 14, so e14a2 is the dominant transcript with a
fraction of e13a2 expressed due to alternative splicing.25
Despite the small number of patients with each transcript
type, we were able to show a significant difference in
expression per cell at multiple time points during treat-
ment. These findings require independent confirmation in
a larger cohort. When treatment decisions are made
according to molecular landmark responses, this may lead
to incorrect classification of some e13a2 patients as opti-
mal responders, and could contribute to adverse out-
comes. Intriguingly, we identified 3 e13a2 patients who at
diagnosis had discordant low BCR-ABL1 mRNA values
(<10%) despite having close to 100% BCR-ABL1I-positive
cells by DNA PCR and metaphase karyotyping. All 3 of
these patients experienced treatment failure or warning by
ELN criteria. The significance of this finding is unclear,
given the small number of patients in this subgroup. It is,
however, consistent with the experimental observation
that imatinib sensitivity was reduced in BCR-ABL1-trans-
duced murine cells selected for low BCR-ABL1
expression.26 
The median limit of detection of BCR-ABL1 DNA was
MR5.2 versus MR4.6 for conventional RQ-PCR. This
improvement in sensitivity led to around half of the sam-
ples with undetectable BCR-ABL1 mRNA having measur-
able MRD and extended the period of time in which there
was detectable BCR-ABL1 by around a year. The median
limit of detection for dPCR was MR5.2. These results are
similar to those obtained by Alikian et al., who used dPCR
for both BCR-ABL1 DNA and mRNA, and found higher
sensitivity with the DNA-based assay.6 Whilst the com-
parison of PCR methods was not the aim of this study, we
found that dPCR was more precise, especially at diagno-
sis, but the Fluidigm® system has the disadvantage that
more than 80% of the input DNA is lost in the dead space
of the microfluidic circuit.
More sensitive mRNA-based methods have also been
developed,6,17,27 and comparisons using different technolo-
gy may yield different results. Nevertheless, genomic
DNA-based methods have the advantage of greater speci-
ficity since cross-contamination between samples from
different patients cannot cause false-positive results when
the assays are patient-specific. A previous study showed
that some patients with undetectable BCR-ABL1 mRNA
by RQ-PCR had MRD detected by dPCR, and that these
patients had a lower probability of successful treatment-
free remission (TFR) after imatinib discontinuation.27 In
the ENESTfreedom study of discontinuation of first-line
nilotinib, patients with MR4.5 on every measurement for
12 months prior to stopping nilotinib were more likely to
maintain TFR at 12 months than patients with one or
more results above the MR4.0 threshold.28 More sensitive
PCR methods might, therefore, have clinical utility as a
means of refining estimates of the probability of TFR.
Miminal residual disease measurement by genomic
DNA PCR provides insights into the kinetics of molecular
response that are not provided by conventional RQ-PCR.
The strong correlation between RQ-PCR and DNA-based
PCR in follow-up samples beyond three months indicates
that the major determinant of RQ-PCR values is the num-
ber of circulating leukemic cells, rather than variable
expression of BCR-ABL1. 
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